MeiraGTx Holdings (MGTX) EBITDA (2017 - 2025)
MeiraGTx Holdings' (MGTX) quarterly EBITDA came in at $18.2 million in Q4 2025, up 157.92% YoY from $7.1 million in Q4 2024, and up 139.61% on a QoQ basis from -$46.1 million in Q3 2025.
MeiraGTx Holdings (MGTX) EBITDA (2017 - 2025) Analysis & Trends
MeiraGTx Holdings (MGTX) has 9 years of EBITDA data on file, last reported at $18.2 million in Q4 2025.
- Quarterly EBITDA rose 157.92% year-over-year to $18.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$106.6 million (up 35.87% YoY) and the FY2025 annual result came in at -$114.2 million, up 30.46% from the prior year.
- EBITDA climbed to $18.2 million in Q4 2025, from -$46.1 million in the prior quarter.
- In the past five years, EBITDA ranged from a high of $18.2 million in Q4 2025 to a low of -$48.6 million in Q2 2024.
- A 5-year average of -$27.3 million and a median of -$30.1 million in 2023 frame the typical range for EBITDA.
- Annual changes were most pronounced in 2024 — EBITDA plunged 439.33% — and 2025, when it soared 157.92%.
- Tracing MGTX's EBITDA over 5 years: stood at -$7.7 million in 2021, then sank by 433.88% to -$41.1 million in 2022, then surged by 122.6% to $9.3 million in 2023, then sank by 439.33% to -$31.5 million in 2024, then soared by 157.92% to $18.2 million in 2025.
- The last three EBITDA figures came in at $18.2 million (Q4 2025), -$46.1 million (Q3 2025), and -$38.8 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | MeiraGTx Holdings | 1.10 Bn | 1.03 Bn | - | 18.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 18.24 Mn |
| Sep 30, 2025 | -46.05 Mn |
| Jun 30, 2025 | -38.80 Mn |
| Mar 31, 2025 | -39.98 Mn |
| Dec 31, 2024 | -31.49 Mn |
| Sep 30, 2024 | -39.33 Mn |
| Jun 30, 2024 | -48.62 Mn |
| Mar 31, 2024 | -46.77 Mn |
| Dec 31, 2023 | 9.28 Mn |
| Sep 30, 2023 | -32.76 Mn |
| Jun 30, 2023 | -28.79 Mn |
| Mar 31, 2023 | -31.76 Mn |
| Dec 31, 2022 | -41.06 Mn |
| Sep 30, 2022 | -22.81 Mn |
| Jun 30, 2022 | -23.76 Mn |
| Mar 31, 2022 | -28.73 Mn |
| Dec 31, 2021 | -7.69 Mn |
| Sep 30, 2021 | -22.55 Mn |
| Jun 30, 2021 | -20.48 Mn |
| Mar 31, 2021 | -22.03 Mn |